(Total Views: 491)
Posted On: 02/15/2021 2:09:57 PM
Post# of 154867
Re: reallypeople? #77971
Yes, severe vs. critical is certainly a difference maker.
I have no clue on the severe vs. critical patient populations of CD12 vs. other reports.
TechGuru has some thoughtful posts on this in the last few days on this message board, i think. His analysis was that CD12 may have a sicker patient population, more skewed towards critical, than other human trial reported recently. At least that's what I think he said
The formula for CD12 mortality works like this:
(1/3)*(Placebo mortality %) + (2/3)*(LL mortality %) = 87/393
Maybe its not 87, but 87 should be in the ballpark unless many of the deaths are outside of 28 days, which the aviptadil reports say they could be.
If placebo mortality % = 33 in CD12, then LL is a massive win.
I have no clue on the severe vs. critical patient populations of CD12 vs. other reports.
TechGuru has some thoughtful posts on this in the last few days on this message board, i think. His analysis was that CD12 may have a sicker patient population, more skewed towards critical, than other human trial reported recently. At least that's what I think he said
The formula for CD12 mortality works like this:
(1/3)*(Placebo mortality %) + (2/3)*(LL mortality %) = 87/393
Maybe its not 87, but 87 should be in the ballpark unless many of the deaths are outside of 28 days, which the aviptadil reports say they could be.
If placebo mortality % = 33 in CD12, then LL is a massive win.
(1)
(0)
